Literature DB >> 12216946

Natural killer cells and their receptors.

Derek Middleton1, Martin Curran, Lynne Maxwell.   

Abstract

Natural killer (NK) cells have been known for a long time to be a very important component of the innate immune system. However, it is only during the last 10 years that knowledge of their receptors has emerged. Described in the present review are those receptor families killer inhibitory receptor (KIR) (belonging to the immunoglobulin superfamily), and killer lectin like receptor (KLR) CD94/NKG2, that both use HLA as a ligand and have inhibiting and activating types of receptors, and natural cytotoxic receptors (NCR) which do not associate with HLA. Association of the receptor gives rise to either an inhibiting or activating signal leading to either failure or success in lysing a target cell. The KIR receptors are very polymorphic both in the number of genes expressed in an individual and the alleles present for a gene. They would appear to have had a rapid evolution compared to the CD94/NKG2 receptors. The roles that NK cells and their receptors have with various facets of transplantation, disease, pregnancy and control of virus infection in humans are described.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12216946     DOI: 10.1016/s0966-3274(02)00062-x

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  39 in total

1.  Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.

Authors:  Anindya Dasgupta; Jordan E Shields; H Trent Spencer
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

2.  Analysis of HLA-ABC locus-specific transcription in normal tissues.

Authors:  Ana Belén García-Ruano; Rosa Méndez; José María Romero; Teresa Cabrera; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Immunogenetics       Date:  2010-09-15       Impact factor: 2.846

3.  Does prolonged cycling of moderate intensity affect immune cell function?

Authors:  J Scharhag; T Meyer; H H W Gabriel; B Schlick; O Faude; W Kindermann
Journal:  Br J Sports Med       Date:  2005-03       Impact factor: 13.800

Review 4.  Human dendritic cell subsets for vaccination.

Authors:  Peter Dubsky; Hideki Ueno; Bernard Piqueras; John Connolly; Jacques Banchereau; A Karolina Palucka
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

5.  KIR haplotype content at the allele level in 77 Northern Irish families.

Authors:  D Middleton; A Meenagh; P A Gourraud
Journal:  Immunogenetics       Date:  2007-01-03       Impact factor: 2.846

6.  HLA-B51 gene and its expression in association with Behçet's Disease in Denizli Province of Turkey.

Authors:  Ayfer Atalay; Sanem Yildiz-Demirtepe; Sinan Tatlipinar; Berna Sanli-Erdoğan; Veli Cobankara; Cem Yildirim; Hüseyin Bağci; Erol Omer Atalay
Journal:  Mol Biol Rep       Date:  2007-06-27       Impact factor: 2.316

Review 7.  Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2012-12-28

8.  Killer-cell immunoglobulin-like receptor genotyping and HLA killer-cell immunoglobulin-like receptor-ligand identification by real-time polymerase chain reaction.

Authors:  H A Hong; A S Loubser; D de Assis Rosa; V Naranbhai; W Carr; M Paximadis; D A Lewis; C T Tiemessen; C M Gray
Journal:  Tissue Antigens       Date:  2011-09

9.  Presence of more activating KIR genes is associated with Hashimoto's thyroiditis.

Authors:  Elham Ashouri; Mohammad Hossein Dabbaghmanesh; Gholamhossein Ranjbar Omrani
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

10.  Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.

Authors:  Wen-Xian Li; Hai-Feng Pan; Jian-Li Hu; Chang-Zhong Wang; Ning Zhang; Jing Li; Xiang-Pei Li; Jian-Hua Xu; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2009-12-10       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.